Literature DB >> 17721935

Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis.

Andrew J Lickteig1, Craig D Fisher, Lisa M Augustine, Nathan J Cherrington.   

Abstract

Nonalcoholic fatty liver disease encompasses a spectrum of hepatic pathologies ranging from simple fatty liver to an inflammatory state known as nonalcoholic steatohepatitis (NASH). NASH is also characterized by severe hepatic oxidative stress. The goal of this study was to determine whether genes of the antioxidant response are induced in rodent models of nonalcoholic fatty liver disease. To simulate simple fatty liver and NASH, respectively, male Sprague-Dawley rats were fed a high-fat (HF) or a methionine and choline-deficient (MCD) diet for 8 weeks. Key marker genes of the antioxidant response that are known to undergo upregulation via activation of Nuclear Factor Erythroid 2-Related Factor 2 were measured using the branched DNA signal amplification assay. Messenger RNA levels of the antioxidant response, including NAD(P)H:quinone oxidoreductase-1 (Nqo1), Glutamate cysteine ligase catalytic (Gclc), and Heme oxygenase-1 (Ho-1), were significantly induced in MCD rat liver but not in HF rat liver. Furthermore, Nqo1 protein expression and activity underwent significant upregulation in MCD rat liver but not in HF rat liver. These data strongly indicate that the pathology induced by the MCD dietary model of NASH results in upregulation of the antioxidant response in rats.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17721935     DOI: 10.1002/jbt.20177

Source DB:  PubMed          Journal:  J Biochem Mol Toxicol        ISSN: 1095-6670            Impact factor:   3.642


  16 in total

1.  Heme oxygenase-1 gene promoter polymorphism and the risk of pediatric nonalcoholic fatty liver disease.

Authors:  P-F Chang; Y-C Lin; K Liu; S-J Yeh; Y-H Ni
Journal:  Int J Obes (Lond)       Date:  2015-04-03       Impact factor: 5.095

2.  H1-antihistamines exacerbate high-fat diet-induced hepatic steatosis in wild-type but not in apolipoprotein E knockout mice.

Authors:  Vineesh V Raveendran; Karen M Kassel; Donald D Smith; James P Luyendyk; Kurt J Williams; Rachel Cherian; Gregory A Reed; Colleen A Flynn; Iván L Csanaky; Andrew L Lickteig; Matthew J Pratt-Hyatt; Curtis D Klaassen; Kottarappat N Dileepan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-05-22       Impact factor: 4.052

Review 3.  Drug metabolism alterations in nonalcoholic fatty liver disease.

Authors:  Matthew D Merrell; Nathan J Cherrington
Journal:  Drug Metab Rev       Date:  2011-05-25       Impact factor: 4.518

Review 4.  Drug disposition in pathophysiological conditions.

Authors:  Adarsh Gandhi; Bhagavatula Moorthy; Romi Ghose
Journal:  Curr Drug Metab       Date:  2012-11       Impact factor: 3.731

5.  Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Matthew D Merrell; Rhiannon N Hardwick; Amy M Bataille; Sarah N Campion; Daniel W Ferreira; Stavra A Xanthakos; Jose E Manautou; H Hesham A-Kader; Robert P Erickson; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2015-03-18       Impact factor: 3.922

6.  Nonalcoholic Steatohepatitis Modulates Membrane Protein Retrieval and Insertion Processes.

Authors:  A L Dzierlenga; J D Clarke; N J Cherrington
Journal:  Drug Metab Dispos       Date:  2016-09-07       Impact factor: 3.922

Review 7.  Molecular mechanisms involved in NAFLD progression.

Authors:  Mariano Malaguarnera; Michelino Di Rosa; Ferdinando Nicoletti; Lucia Malaguarnera
Journal:  J Mol Med (Berl)       Date:  2009-04-08       Impact factor: 4.599

8.  Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats.

Authors:  Craig D Fisher; Andrew J Lickteig; Lisa M Augustine; Ronald P J Oude Elferink; David G Besselsen; Robert P Erickson; Nathan J Cherrington
Journal:  Eur J Pharmacol       Date:  2009-04-07       Impact factor: 4.432

9.  Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis.

Authors:  Craig D Fisher; Jonathan P Jackson; Andrew J Lickteig; Lisa M Augustine; Nathan J Cherrington
Journal:  Arch Toxicol       Date:  2008-05-17       Impact factor: 5.153

10.  Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease.

Authors:  Rhiannon N Hardwick; Craig D Fisher; Mark J Canet; April D Lake; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2010-08-30       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.